In a study appearing in Nature Chemistry, researchers at the University of California, Davis Institute for Psychedelics and Neurotherapeutics (IPN) report the successful total synthesis of ibogaine, ibogaine analogues and related compounds from pyridine — a relatively inexpensive and widely available chemical.
Delix Therapeutics recently announced that the first neuroplastogen drug based on UC Davis Institute for Psychedelics and Neurotherapeutics (IPN) research will be tested in patients with major depressive disorder.
New research shows that the anti-anxiety and hallucinogenic-like effects of a psychedelic drug work through different neural circuits. The study, in a mouse model, shows that it could be possible to separate treatment from hallucinations when developing new drugs based on psychedelics.
Our bodies are pharmaceutical factories, but did you know that our bodies also naturally produce psychedelics? Why do we make them? How do they work? What are their functions? And can we leverage them to mitigate neurodegenerative and neuropsychiatric conditions? The UC Davis Institute for Psychedelics and Neurotherapeutics is exploring those questions.
